[go: up one dir, main page]

WO2008012031A3 - Blockers of gsk3 for the prevention and treatment of pemphigus vulgaris - Google Patents

Blockers of gsk3 for the prevention and treatment of pemphigus vulgaris Download PDF

Info

Publication number
WO2008012031A3
WO2008012031A3 PCT/EP2007/006464 EP2007006464W WO2008012031A3 WO 2008012031 A3 WO2008012031 A3 WO 2008012031A3 EP 2007006464 W EP2007006464 W EP 2007006464W WO 2008012031 A3 WO2008012031 A3 WO 2008012031A3
Authority
WO
WIPO (PCT)
Prior art keywords
pemphigus vulgaris
blockers
prevention
treatment
gsk3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/006464
Other languages
French (fr)
Other versions
WO2008012031A2 (en
Inventor
Eliane Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Bern
Original Assignee
Universitaet Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Bern filed Critical Universitaet Bern
Publication of WO2008012031A2 publication Critical patent/WO2008012031A2/en
Publication of WO2008012031A3 publication Critical patent/WO2008012031A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a method of preventing and treating pemphigus vulgaris comprising administering a GSK3 blocker, and the use of such blockers in said prevention and treatment and in the manufacture of medicaments for preventing and treating pemphigus vulgaris. In particular the invention relates to a method of preventing and treating pemphigus vulgaris comprising administering a GSK3β blocker, and the use of such blockers in said prevention and treatment and in the manufacture of medicaments for preventing and treating pemphigus vulgaris. Preferred is the use of GSK3β blockers which are selective for GSK3β, i.e. which selectively reduce enzyme activity of GSK3β but not to a reasonable extent of GSK3α.
PCT/EP2007/006464 2006-07-25 2007-07-20 Blockers of gsk3 for the prevention and treatment of pemphigus vulgaris Ceased WO2008012031A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06015408 2006-07-25
EP06015408.5 2006-07-25

Publications (2)

Publication Number Publication Date
WO2008012031A2 WO2008012031A2 (en) 2008-01-31
WO2008012031A3 true WO2008012031A3 (en) 2008-04-17

Family

ID=38608721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/006464 Ceased WO2008012031A2 (en) 2006-07-25 2007-07-20 Blockers of gsk3 for the prevention and treatment of pemphigus vulgaris

Country Status (1)

Country Link
WO (1) WO2008012031A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086814A2 (en) * 2004-03-09 2005-09-22 The Uab Research Foundation Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3)
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
WO2007075911A2 (en) * 2005-12-22 2007-07-05 Yale University Inhibition of glycogen synthase kinase and methods of treating autoimmune or immune inflammatory disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086814A2 (en) * 2004-03-09 2005-09-22 The Uab Research Foundation Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3)
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
WO2007075911A2 (en) * 2005-12-22 2007-07-05 Yale University Inhibition of glycogen synthase kinase and methods of treating autoimmune or immune inflammatory disease

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
COGHLAN M P ET AL: "SELECTIVE SMALL MOLECULE INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 MODULATE GLYCOGEN METABOLISM AND GENE TRANSCRIPTION", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 7, no. 10, 2000, pages 793 - 803, XP001057051, ISSN: 1074-5521 *
KODAMA SHINYA ET AL: "Axin directly interacts with plakoglobin and regulates its stability", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 39, 24 September 1999 (1999-09-24), pages 27682 - 27688, XP002470030, ISSN: 0021-9258 *
LECLERC S ET AL: "Indirubins Inhibit Glycogen Synthase Kinase-3b and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 1, 5 January 2001 (2001-01-05), pages 251 - 260, XP002188391, ISSN: 0021-9258 *
MEIJER L ET AL: "Pharmacological inhibitors of glycogen synthase kinase 3", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 25, no. 9, 2004, pages 471 - 480, XP002326405, ISSN: 0165-6147 *
MUZIO LORENZO LO ET AL: "Strict correlation between uPAR and plakoglobin expression in pemphigus vulgaris", JOURNAL OF CUTANEOUS PATHOLOGY, vol. 29, no. 9, October 2002 (2002-10-01), pages 540 - 548, XP002470031, ISSN: 0303-6987 *
PELACHO B ET AL: "Pemphigus vulgaris autoantibodies induce apoptosis in HaCaT keratinocytes", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 566, no. 1-3, 21 May 2004 (2004-05-21), pages 6 - 10, XP004509313, ISSN: 0014-5793 *
POWELL A M ET AL: "Pemphigus: Pathogenic mechanisms and potential therapeutic targets", DRUG DISCOVERY TODAY: DISEASE MECHANISMS, ELSEVIER, vol. 2, no. 2, 2005, pages 269 - 274, XP004978880, ISSN: 1740-6765 *
SCHULZE K ET AL: "Pemphigus vulgaris identifies non-junctional desmoglein 3 as regulator of tissue homeostasis via plakoglobin signaling", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 127, no. Suppl. 1, April 2007 (2007-04-01), & 68TH ANNUAL MEETING OF THE SOCIETY-FOR-INVESTIGATIVE-DERMATOLOGY; LOS ANGELES, CA, USA; MAY 09 -12, 2007, pages S81, XP009095480, ISSN: 0022-202X *
WILLIAMS C L ET AL: "Reduced expression of Wnt-1 and E-cadherin, and diminished beta-catenin stability in MCF-7 breast cancer cells that overexpress protein kinase C-alpha", INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,, GR, vol. 19, no. 6, December 2001 (2001-12-01), pages 1227 - 1233, XP002394272, ISSN: 1019-6439 *
WILLIAMSON LINA ET AL: "Pemphigus vulgaris identifies plakoglobin as key suppressor of c-Myc in the skin", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 25, no. 14, July 2006 (2006-07-01), pages 3298 - 3309, XP002470032, ISSN: 0261-4189 *

Also Published As

Publication number Publication date
WO2008012031A2 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
WO2009109911A8 (en) Methods of treating chronic pain
KZ24152B (en) Method of photosensitizer activation, treatment method with application of activated photosensitizer and photosensitizer application to prepare medicine
MX2010006823A (en) Methods for the treatment of gout.
WO2007146411A3 (en) Nanoshell therapy
WO2008060877A3 (en) Medical devices and related methods
WO2007112052A3 (en) Formulations and methods for vascular permeability-related diseases or conditions
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
UA100111C2 (en) Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
WO2008122049A3 (en) Methods and compositions for reduction of side effects of therapeutic treatments
WO2008082887A3 (en) Inhibitors of poly(adp-ribose)polymerase
WO2009109908A8 (en) Methods of treating inflammatory pain
WO2007120936A3 (en) Use.of vildagliptin for the treatment of diabetes
WO2010092123A8 (en) Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
WO2007089454A3 (en) Methods for enhancing skin treatments
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
IL195254A0 (en) Simultaneous, separate or sequential therapeutic use of at least one botulinum neurotoxin and of at least one opiate derivative
WO2008029169A3 (en) Method of treating respiratory disorders
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
EP2203169A4 (en) Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors
WO2007081879A3 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
FI20050023L (en) Wood treatment agent, method for treating wood and wood product
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2008105826A3 (en) Compositions compromising lysostaphin variants and methods of using the same
WO2007130501A3 (en) Combination therapy for treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07765244

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07765244

Country of ref document: EP

Kind code of ref document: A2